Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
ID: 322177Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/322177

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-20-043.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for Cancer Center Support Grants (CCSGs) aimed at enhancing cancer research within NCI-designated Cancer Centers. This funding opportunity, specifically the P30 Clinical Trial Optional grants, is designed to support both Comprehensive Cancer Centers and Cancer Centers that integrate various research disciplines, fostering a collaborative environment to advance understanding and treatment of cancer. The CCSGs are crucial for establishing a robust research infrastructure that promotes innovative cancer research initiatives across the United States, with applications subject to peer review and a maximum budget limit for new and renewal requests. Interested applicants can find more information and guidelines at the NIH website, and the application deadline is set for October 12, 2121.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PAR-20-043.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting applications for Cancer Center Support Grants (CCSGs) aimed at promoting cancer research within NCI-designated Cancer Centers. This funding opportunity (PAR-20-043), particularly the P30 Clinical Trial Optional grants, supports comprehensive, clinical, and basic cancer centers to foster a collaborative research environment that integrates various scientific disciplines. The initiative encourages applications from institutions with significant annual NIH cancer-focused funding and promotes innovative interactions, community engagement, and education within the realm of cancer research. The program not only aims to enhance the understanding of cancer but also to improve prevention, diagnosis, and therapeutic strategies, reflecting the NCI’s commitment to advancing cancer science and public health. Applications must comply with specified guidelines and are subject to peer review, with a maximum budget limit established for new and renewal applications. The CCSGs are foundational for research infrastructure, enabling extensive cancer-focused initiatives across the United States.
    Similar Opportunities
    Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for Cancer Center Support Grants (CCSGs) aimed at supporting NCI-designated Cancer Centers through the P30 funding mechanism. This initiative seeks to enhance collaborative cancer research across various domains, including basic laboratory, clinical, and prevention research, with eligibility extending to Comprehensive Cancer Centers, Clinical Cancer Centers, and Basic Cancer Centers that demonstrate significant research capabilities and community engagement. The funding, which has an award ceiling of $1.5 million, is intended to foster transdisciplinary research collaboration, create shared resources, and ensure equitable participation in cancer research across diverse populations. Interested applicants must submit their proposals by January 7, 2026, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at supporting the planning of clinical trials that enhance cancer prevention, detection, and survivorship. This program seeks to address critical gaps in preliminary data, participant recruitment strategies, and study designs necessary for finalizing trial protocols, thereby facilitating effective cancer intervention trials aligned with public health goals. Eligible organizations, including higher education institutions and nonprofits, can apply for funding of up to $225,000 per year for a maximum of three years, with a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. Interested applicants should note the open submission date of January 25, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research," aimed at encouraging revision applications from currently funded NCI P50 specialized centers. This initiative seeks to expand existing research by integrating new technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program, promoting interdisciplinary collaboration to enhance cancer research effectiveness and validation of these technologies. The funding, estimated at $150,000 per award with a total of three awards available, is intended to support projects that aim to reduce cancer risks, improve screening and diagnostic methods, and advance cancer treatments. Applications are due by 5:00 PM local time on October 3, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating the planning of clinical trials that enhance cancer prevention, intervention, and survivor care. This program seeks to address critical information gaps that hinder effective trial protocols, including population characteristics and operational risks, by requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams and participant recruitment. With funding of up to $225,000 per year available for planning initiatives, eligible organizations include higher education institutions, non-profits, and tribal governments, with a project period of up to three years. Interested applicants should note the submission deadline of January 25, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Environmental Health Sciences Core Centers Program (P30 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Environmental Health Sciences Core Centers Program (EHSCC), aimed at establishing research hubs that focus on environmental health science. This program seeks to enhance understanding of the impact of environmental exposures on human health, with an emphasis on interdisciplinary collaboration among investigators and community engagement, as outlined in the NIEHS Strategic Plan for 2025-2029. Eligible applicants include a variety of organizations such as higher education institutions and nonprofits, with a requirement for demonstrated peer-reviewed research funding of at least $3 million annually. The NIH plans to commit $6 million to fund up to four awards, with the earliest application submission date set for February 18, 2025, and a final close date of January 29, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NCI Research Specialist (Core-based Scientist) Award (R50), a federal grant aimed at supporting laboratory-based scientists involved in cancer research. This funding opportunity is designed to provide salary support and promote stable career paths for exceptional researchers who contribute significantly to NCI-funded projects but do not serve as independent investigators. The initiative emphasizes the importance of collaborative scientific support in advancing cancer research and aims to foster a sustainable research workforce, particularly among institutions serving underrepresented groups. Applications are open from October 2, 2023, with awards expected as early as November 2023, and interested parties can find more information and submit inquiries via grantsinfo@nih.gov. The project duration can extend up to five years, with funding covering the Research Specialist's salary and limited travel costs.